Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Evotec SE

    NASDAQ: EVO · Real-Time Price · USD
    4.13
    -0.14 (-3.28%)
    At close: Jun 16, 2025, 3:59 PM
    4.19
    1.58%
    After-hours: Jun 16, 2025, 07:52 PM EDT
    -3.28%
    Bid 2.99
    Market Cap 1.46B
    Revenue (ttm) 788.22M
    Net Income (ttm) -206.98M
    EPS (ttm) -0.67
    PE Ratio (ttm) -6.16
    Forward PE -71.33
    Analyst Hold
    Ask 5.26
    Volume 394,322
    Avg. Volume (20D) 130,901
    Open 4.14
    Previous Close 4.27
    Day's Range 4.06 - 4.22
    52-Week Range 2.84 - 5.64
    Beta 1.09

    About EVO

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol EVO
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for EVO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Evotec SE is scheduled to release its earnings on Aug 13, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 months ago
    +10.09%
    Evotec shares are trading higher. The company repo... Unlock content with Pro Subscription
    6 months ago
    -16.07%
    Evotec shares are trading lower after Halozyme withdrew its €2 billion proposal to acquire the company.
    news image

    1 month ago · accessnewswire.com

    Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments

    Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations. The collaboration continues a successful partn...

    news image

    1 month ago · seekingalpha.com

    Evotec SE (EVO) Q1 2025 Earnings Call Transcript

    Evotec SE (NASDAQ:EVO ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Volker Braun - Head, Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hitchin...

    news image

    1 month ago · accessnewswire.com

    Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment

    Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentum Strong progress in strategic protein degradation pa...

    news image

    1 month ago · accessnewswire.com

    Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025

    HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 20...

    news image

    1 month ago · accessnewswire.com

    Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb

    Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs Performance-based and program-based payments of in total US$ 75 m to Evotec HAMBURG, DE /...

    news image

    2 months ago · seekingalpha.com

    Evotec SE (EVO) Q4 2024 Earnings Call Transcript

    Evotec SE (NASDAQ:EVO ) Q4 2024 Earnings Conference Call April 17, 2025 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hi...

    news image

    2 months ago · accessnewswire.com

    Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results

    Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth, high-value ...

    news image

    2 months ago · accessnewswire.com

    Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025

    HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 Ap...

    Add to Watchlist